

# Join

## the New Era of ASPET

### Benefits of ASPET membership

- Reduced page charges to publish in ASPET journals – pay \$35/page instead of \$70/page and save enough with one five-page article to pay the \$130 annual ASPET dues!
- Reduced fees to publish color figures in ASPET journals – pay \$200/figure instead of \$400/figure.
- Subscriptions to *Molecular Interventions* and *The Pharmacologist* included with membership.
- Reduced rates for ASPET print journals
  - The Journal of Pharmacology and Experimental Therapeutics* (monthly)
  - Pharmacological Reviews* (quarterly)
  - Drug Metabolism and Disposition* (monthly)
  - Molecular Pharmacology* (monthly)
  - Clinical Pharmacology and Therapeutics* (monthly)
- Free full-text access to five online Society journals (*JPET, Pharm Rev, DMD, Mol Pharm & Molecular Interventions*).
- Reduced registration fees for ASPET meetings and ASPET Colloquia.
- Free listing in the FASEB Directory and subscriptions to the *FASEB Newsletter* and to *The Scientist*.
- Public affairs advocacy for increased research funding and science policy favorable to pharmacology and biomedical research in general.
- Low annual dues: Regular ASPET membership only \$130/year; Affiliate membership \$105/yr. Student membership is free for one year.

Visit us on the Web at [www.aspet.org](http://www.aspet.org)  
or send us an e-mail ([info@aspnet.org](mailto:info@aspnet.org)).



## Washington DC Principles

# for FREE ACCESS to SCIENCE

[www.dcpinciples.org](http://www.dcpinciples.org)

## The 7 Principles

- 1** As not-for-profit publishers, we see it as our mission to maintain and enhance the independence, rigor, trust, and visibility that have established scholarly journals as reliable filters of information emanating from clinical and laboratory research.
- 2** As not-for-profit publishers, we reinvest all of the revenue from our journals in the direct support of science worldwide, including scholarships, scientific meetings, grants, educational outreach, advocacy for research funding, the free dissemination of information for the public, and improvements in scientific publishing.
- 3** As not-for-profit publishers, we have introduced and will continue to support the following forms of free access:
  - a. Selected important articles of interest are free online from the time of publication;
  - b. The full text of our journals is freely available to everyone worldwide either immediately or within months of publication, depending on each publisher's business and publishing requirements;
  - c. The content of our journals is available free to scientists working in many low-income nations;
  - d. Articles are made available free online through reference linking between these journals;
  - e. Our content is available for indexing by major search engines so that readers worldwide can easily locate information.
- 4** We will continue to work to develop long-term preservation solutions for online journals to ensure the ongoing availability of the scientific literature.
- 5** We will continue to work with authors, peer-reviewers, and editors for the development of robust online and electronic tools to improve efficiency of their important intellectual endeavors.
- 6** We strongly support the principle that publication fees should not be borne solely by researchers and their funding institutions, because the ability to publish in scientific journals should be available equally to all scientists worldwide, no matter what their economic circumstances.
- 7** As not-for-profit publishers, we believe that a free society allows for the co-existence of many publishing models, and we will continue to work closely with our publishing colleagues to set high standards for the scholarly publishing enterprise.

## ...About the Washington DC Principles

The Washington DC Principles is a commitment from 50 (and growing) medical/scientific societies and publishers to provide free access and wide dissemination of published research findings.

The DC Principles provide what has been called the needed "middle ground" in the increasingly heated debate between those who advocate immediate unfettered online access to medical and scientific research findings and advocates of the current journal publishing system. The document was drafted in response to recent claims that these publishers' practices hinder the public's ability to access published scientific research.



**FOR MORE INFORMATION,  
CONTACT:**  
**The American  
Physiological Society,**  
9650 Rockville Pike,  
Bethesda, MD 20814-3991 (USA),  
Phone: 301-634-7118,  
Fax: 301-634-7241,  
E-mail: [mfrank@the-aps.org](mailto:mfrank@the-aps.org),  
Web: [www.dcpinciples.org](http://www.dcpinciples.org)



The Orphan Drug Act, as well as the equally successful Hatch-Waxman Act, resulted from productive collaboration and compromise between legislators of widely opposing political views. Today's Congress would do well to take note and adopt a similar strategy. 📄 doi:10.1124/mi.6.4.2

#### References

1. NORD Fact Sheet. National Organization for Rare Disorders, Inc., Danbury, CT, undated.
2. Ross, W.R. How industry learned to love—and profit by—the Orphan Drug Act. *Medical Marketing & Media* **32**, 40–47 (1997).
3. Orphan Drug Act, Pub. L. No.97-414 (1984 as amended).
4. Orphan Products Designation and Approvals List. <http://www.fda.gov/orphan/designat/list.htm> Accessed May 2, 2006.
5. Haffner, M.E. Adopting orphan drugs—two dozen years of treating rare diseases. *N. Engl. J. Med.* **354**, 445–447 (2006).
6. Bridges, A. 1<sup>st</sup> treatment for rare disease gets OK. *Phila. Inquirer*, April 29, 2006.
7. *Physicians' Desk Reference*, 60th ed. Thomson PDR, Montvale, NJ, pp. 1263–1264 (2006).
8. Scheindlin, S. When she says yes, but he needs NO: Some reflections on nitric oxide. *Mol. Interv.* **6**, 8–13 (2006).
9. Galie, N., Ghofrani, H.A., Torbicki, A. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. *N. Engl. J. Med.* **353**, 2148–2157 (2005).
10. Scheindlin, S. An intimate history of an orphan drug. *Pharmacy Times* **63**, 42–46 (1997).
11. Kumar, P.D. Thiamine shortage—plight of low-cost lifesaving orphan drugs. *N. Engl. J. Med.* **354**, 532–533 (2006).
12. Anonymous. Discontinuation of spectinomycin. *JAMA* **295**, 2245 (2006).
13. Scheindlin, S. Antimalarials: Shortages and searches. *Mol. Interv.* **5**, 268–272 (2005).
14. Voelker, R. New drug formulations offer hope for easing global burden of malaria. *JAMA* **295**, 485–486 (2006).
15. Herper, M. Breathless—victims of a rare and deadly lung disease are getting hope from a slew of new biotech drugs. *Forbes* p. 75, January 30, 2006.
16. Carrel, L. Breathless enthusiasm. [www.smartmoney.com](http://www.smartmoney.com) December 12, 2005. Accessed January 19, 2006.
17. Druker, B.J. Circumventing resistance to kinase-inhibitor therapy. *N. Eng. J. Med.* **354**, 2594–2596 (2006).
18. Hampton, T. Rare diseases research gets boost. *JAMA* **295**, 2836–2838 (2006).



**Stanley Scheindlin, DSc, RPh**, holds graduate degrees in pharmaceutical chemistry and worked in drug product development and regulatory affairs. Now retired, he is a part-time consultant and writes freelance articles for pharmacy-related specialty publications.

## Improving research protections means improving research quality.



### Demonstrate your organization's commitment to human research protections through accreditation.

AAHRPP accreditation...

- improves your human research protection program
- assists your organization in achieving regulatory compliance
- helps your organization compete for sponsored research
- “raises the bar” in overall research quality
- builds and enhances public trust

**AAHRPP**  
Association for the Accreditation of  
Human Research Protection Programs, Inc.®

**FASEB**  
AAHRPP Founding Member

For information call (202)783-1112  
[www.aahrpp.org](http://www.aahrpp.org)

# *Why Publish with ASPET?*

*Because ASPET gives you these advantages:*

- ◆ **Low Page Charges** — \$35/page for ASPET members, \$70/page for nonmembers (publishing one paper saves the \$125 membership dues)
- ◆ **Low Color Fees** — \$200/color figure for ASPET members, \$400/color figure for nonmembers
- ◆ **Online Manuscript Submission** — submit your manuscript 24/7 — whenever it suits your schedule; online peer review reduces review times; track the progress of your manuscript through the review process
- ◆ **Publish Online Ahead of Print** — manuscripts are published online shortly after acceptance — at least two months prior to print publication
- ◆ **Wide Dissemination** — accepted manuscripts are freely accessible *immediately*; fully formatted articles are freely accessible 12 months after publication; low-cost pay-per-view option for nonsubscribers; abstracts and tables of contents always freely accessible

The Journal of  
**PHARMACOLOGY**  
and Experimental Therapeutics


**MOLECULAR  
PHARMACOLOGY**

**DRUG METABOLISM  
AND DISPOSITION**

*Visit [www.aspetjournals.org](http://www.aspetjournals.org) to access each ASPET journal.*



ASPET Journals — Widely Read, Highly Respected



# EXPERIMENTAL BIOLOGY 2007

Today's Research: TOMORROW'S HEALTH

**April 28–May 2**

The Washington Convention Center, Washington DC

## **PARTICIPATING SOCIETIES**

American Association of Anatomists (AAA)

The American Physiological Society (APS)

American Society for Biochemistry and Molecular Biology (ASBMB)

American Society for Investigative Pathology (ASIP)

American Society for Nutrition (ASN)

American Society for Pharmacology and Experimental Therapeutics (ASPET)

**For further information, contact [eb@faseb.org](mailto:eb@faseb.org) or visit [www.eb2007.org](http://www.eb2007.org)**

9650 Rockville Pike, Bethesda, MD 20814 • 301.634.7010 • Fax: 301.634.7014

